Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.60 |
| ▸ | PHGDH | O43175 | 1/20 | 0.60 |
| ▸ | NAMPT | P43490 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3937303 | 0.86 | EPHX2 (0.77) | SMN1; SMN2EPHX2PHGDHNAMPTNPC1 | |
| SCHEMBL4915213 | 0.85 | CNR1 (0.72) | CNR1SMN1; SMN2EPHX2NPC1LMNA | |
| SCHEMBL22834266 | 0.80 | CNR1 (1.00) | CNR1SMN1; SMN2NPC1LMNAMAPT | |
| (4-Chlorophenyl)(Morpholino)Methanone SCHEMBL6937394 | 0.78 | PHGDH (1.00) | SMN1; SMN2PHGDHALDH1A1MAPTHPGD | |
| SCHEMBL22834260 | 0.76 | SMN1; SMN2 (1.00) | CNR1SMN1; SMN2EPHX2ALDH1A1LMNA | |
| SCHEMBL19472655 | 0.75 | CNR1 (0.88) | CNR1SMN1; SMN2NPC1LMNAMAPT | |
| SCHEMBL3945175 | 0.75 | EPHX2 (1.00) | SMN1; SMN2EPHX2PHGDHNPC1ALDH1A1 | |
| SCHEMBL26546711 | 0.75 | SMN1; SMN2 (0.57) | CNR1SMN1; SMN2EPHX2NAMPTNPC1 | |
| SCHEMBL20388937 | 0.75 | NAMPT (1.00) | EPHX2NAMPT | |
| SCHEMBL3943499 | 0.74 | EPHX2 (0.80) | SMN1; SMN2EPHX2PHGDHNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | claimed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786422-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | Prosidion Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006018662-A2 | ARYL UREA DERIVATIVES FOR TREATING OBESITY | PROSIDION LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | CNR1 1/4885SMN1; SMN2 3931/4885EPHX2 2759/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | CNR1 1/4885SMN1; SMN2 3931/4885EPHX2 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.